Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation and Depletion: 2016-2025

Historic Depreciation and Depletion for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to $318,000.

  • Akebia Therapeutics' Depreciation and Depletion fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Depreciation and Depletion of $318,000 as of Q3 2025, which was up 0.63% from $316,000 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Depreciation and Depletion peaked at $408,000 during Q4 2022, and registered a low of $314,000 during Q1 2025.
  • Moreover, its 3-year median value for Depreciation and Depletion was $364,000 (2024), whereas its average is $363,182.
  • As far as peak fluctuations go, Akebia Therapeutics' Depreciation and Depletion rose by 0.76% in 2024, and later fell by 21.00% in 2025.
  • Over the past 4 years, Akebia Therapeutics' Depreciation and Depletion (Quarterly) stood at $408,000 in 2022, then fell by 3.43% to $394,000 in 2023, then decreased by 14.97% to $335,000 in 2024, then fell by 12.40% to $318,000 in 2025.
  • Its Depreciation and Depletion stands at $318,000 for Q3 2025, versus $316,000 for Q2 2025 and $314,000 for Q1 2025.